Development and validation of an HPLC assay for fentanyl, alfentanil, and sufentanil in swab samples

Citation
J. Lambropoulos et al., Development and validation of an HPLC assay for fentanyl, alfentanil, and sufentanil in swab samples, J PHARM B, 23(2-3), 2000, pp. 421-428
Citations number
9
Categorie Soggetti
Chemistry & Analysis
Journal title
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
ISSN journal
07317085 → ACNP
Volume
23
Issue
2-3
Year of publication
2000
Pages
421 - 428
Database
ISI
SICI code
0731-7085(20000815)23:2-3<421:DAVOAH>2.0.ZU;2-D
Abstract
A high performance liquid chromatography (HPLC) method for the assay of fen tanyl citrate, alfentanil hydrochloride, and sufentanil citrate swab sample s was developed and validated in order to control a cleaning procedure. The swabbing procedure involved Super POLX 1200 wipers moistened with water. T he assay employed extraction of swabs with water and analysis by isocratic, reversed-phase, HPLC with varying ultraviolet (UV) detection for desired s ensitivity, depending on the analyte. The method was shown to be selective and linear from the limits of quantitation (0, 10, 0. 20, and 0. 15 mu g/sw ab for fentanyl citrate, alfentanil, and sufentanil, respectively) to over three times these concentrations. The assay limits (detection levels) per s wab area were set at least at 0.2% of the concentrations of the actives in the drug products (0.02. 0. 10, and 0. 1D mu g/swab or approximately 0.03, 0.02, and 0.2% for fentanyl citrate, alfentanil, and sufentanil, respective ly). It should be noted that all active concentrations listed in this work were calculated based on the salt form concentration for fentanyl (citrate salt) and the free base forms for alfentanil and sufentanil, No reference s tandard was available for alfentanil hydrochloride and sufentanil citrate. Drug product was used instead throughout this study. (C) 2000 Elsevier Scie nce B.V. All rights reserved.